Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
The University of Birmingham invites tenders for independent central review of the primary outcome data for the clinical platform trial, Glo-BNHL. The platform aims to test a wide range of therapies over its lifetime in order to find better treatments for the rare paediatric cancer, B-cell non-Hodgkin's Lymphoma. The design allows addition of new treatment arms as novel therapies become available for testing. There are currently 2 treatment arms.
Independent central review of the clinical data that informs the primary outcome measures is required, to include: cross sectional imaging by CT or MRI, PET-CT scan, bone marrow aspirate, bone marrow trephine and lumbar puncture pathology reports.
Glo-BNHL is an international trial with participating sites in the UK, Europe, USA, Canada, Australia, New Zealand and Israel. A total of 45 sites will participate, with international sites' activity coordinated by 15 National Coordinating Centres.
Glo-BNHL recently received ethics approval in the UK and will open later this year. Approval in the other participating nations will follow. An expedient solution to independent central review is therefore required.
This project may be funded by the European Regional Development Fund (ERDF) or;
Please refer to Appendix A via www.in-tendhost.co.uk/universityofbirmingham/aspx/Home for full specification of requirements.
No supplier information available.